Discontinuation
Merck drops IL-2 agonist MK-1484 from its pipeline
Merck has stopped work on MK-1484, the IL-2 agonist it developed with Sutro Biopharma, citing a routine reshuffle of priorities. A second IL-2 asset, MK-6194, no longer appears on its public pipeline, leaving the company without an IL-2 program. Takeda and Innovent are still advancing TAK-928 in a global phase 3 lung cancer study.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.